Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

Β-Catenin is Regulated by USP9x and Mediates Resistance to TRAIL-induced Apoptosis in Breast Cancer.

The Potential Molecular Mechanism of Overexpression of Upa, IL-8, MMP-7 and MMP-9 Induced by TRAIL in Pancreatic Cancer Cell.

Correction to: USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

Deubiquitinating Enzyme USP9X Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer by Stabilizing Snail1.

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

USP9X-mediated Deubiquitination of B-cell CLL/lymphoma 9 Potentiates Wnt Signaling and Promotes Breast Carcinogenesis

USP9X Stabilizes BRCA1 and Confers Resistance to DNA‐damaging Agents in Human Cancer Cells

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

Β-Catenin Decreases Acquired TRAIL Resistance in Non-Small-cell Lung Cancer Cells by Regulating the Redistribution of Death Receptors.

Deubiquitinase Ubiquitin‐specific Protease 9X Regulates the Stability and Function of E3 Ubiquitin Ligase Ring Finger Protein 115 in Breast Cancer Cells

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

The deubiquitinase USP28 stabilizes the expression of RecQ family helicases and maintains the viability of triple negative breast cancer cells

USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potential

USP9X deubiquitinates and stabilizes CDC123 to promote breast carcinogenesis through regulating cell cycle

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

USP37 Promotes Angiogenesis and Metastasis in Colorectal Cancer by Facilitating Β-Catenin Stability.

USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment

Decoy Receptor 2 (dcr2) is a P53 Target Gene and Regulates Chemosensitivity.